参考文献
PubMed=566614
Burk K.H., Drewinko B., Trujillo J.M., Ahearn M.J.
Establishment of a human plasma cell line in vitro.
Cancer Res. 38:2508-2513(1978)
PubMed=7140810; DOI=10.1002/eji.1830120804
Edwards P.A.W., Smith C.M., Neville A.M., O'Hare M.J.
A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
Eur. J. Immunol. 12:641-648(1982)
PubMed=6605913; DOI=10.1016/0165-2478(83)90049-4
Ralph P., Saiki O., Maurer D.H., Welte K.
IgM and IgG secretion in human B-cell lines regulated by B-cell-inducing factors (BIF) and phorbol ester.
Immunol. Lett. 7:17-23(1983)
PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)
PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)
PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)
PubMed=4042077; DOI=10.1002/1097-0142(19851115)56:10<2544::AID-CNCR2820561039>3.0.CO;2-g
Ralph P.
The human B-cell lineage cell line ARH-77.
Cancer 56:2544-2545(1985)
Patent=US4730036
Ralph P., Welte K.
Purifications of B-cell inducing factor (BIF) and B-cell growth factor (BGF).
Patent number US4730036, 08-Mar-1988
PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)
PubMed=8051085; DOI=10.1016/S0021-9258(17)32120-8
Liebersbach B.F., Sanderson R.D.
Expression of syndecan-1 inhibits cell invasion into type I collagen.
J. Biol. Chem. 269:20013-20019(1994)
PubMed=7579375; DOI=10.1182/blood.V86.10.4001.bloodjournal86104001
Pellat-Deceunynck C., Amiot M., Bataille F.-R., Van Riet I., Van Camp B., Omede P., Boccadoro M.
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after.
Blood 86:4001-4002(1995)
PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)
PubMed=10516762; DOI=10.1038/sj.leu.2401510
Drexler H.G., Dirks W.G., MacLeod R.A.F.
False human hematopoietic cell lines: cross-contaminations and misinterpretations.
Leukemia 13:1601-1607(1999)
DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)
PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)
PubMed=14555701
Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Mol. Cancer Ther. 2:825-833(2003)
PubMed=18262052; DOI=10.1016/j.cancergencyto.2007.10.013
Parker H., Cheung K.L., Robinson H.M., Harrison C.J., Strefford J.C.
Cytogenetic and genomic characterization of cell line ARH77.
Cancer Genet. Cytogenet. 181:40-45(2008)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)
